Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License AgreementCompany AnnouncementCOPENHAGEN, Denmark; April 8, 2022 – Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with J...
Source: pharmiweb.com